SCHEMBL19689068

SCHEMBL19689068

CC(C)(C)[Si](C)(C)O[C@@H]1[C@H]2O[Si](C(C)(C)C)(C(C)(C)C)OC[C@H]2O[C@H]1n1cnc2c(C(=O)O)ncnc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STING1 Q86WV6 9/20 0.38
▸ PDE4A P27815 4/20 0.36
▸ PDE4D Q08499 4/20 0.36
▸ LMNA P02545 3/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ ADRB3 P13945 1/20 0.36
▸ PTGS2 P35354 1/20 0.36
▸ PDE3A Q14432 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ RXFP1 Q9HBX9 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ PDE4B Q07343 3/20 0.35
▸ PDE4C Q08493 3/20 0.35
▸ GMNN O75496 1/20 0.35
▸ RAPGEF3 O95398 1/20 0.35
▸ BLM P54132 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ RAPGEF4 Q8WZA2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16871804 0.92 RXFP1 (0.39) STING1PDE4APDE4DLMNACYP1A2
SCHEMBL17363529 0.86 PDE4A (0.44) STING1PDE4APDE4DLMNACYP1A2
SCHEMBL17363528 0.86 PDE4A (0.44) STING1PDE4APDE4DLMNACYP1A2
SCHEMBL18486390 0.84 DNPH1 (0.49) STING1
SCHEMBL18486383 0.82 STING1 (0.35) STING1PDE4APDE4DCYP1A2PDE4B
SCHEMBL16871895 0.82 DNPH1 (0.44) STING1PDE4APDE4DPDE4BPDE4C
SCHEMBL18486384 0.82 STING1 (0.35) STING1PDE4APDE4DCYP1A2PDE4B
SCHEMBL17363663 0.82 DNPH1 (0.44) STING1PDE4APDE4DPDE4BPDE4C
SCHEMBL20547882 0.79 STING1 (0.38) STING1PDE3ARXFP1KMT2A
SCHEMBL17363633 0.79 DNPH1 (0.35) STING1PDE4APDE4DLMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 — — US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 STING1 1024/4885PDE4A 1079/4885PDE4D 2433/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 STING1 1050/4885PDE4A 1065/4885PDE4D 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback